Morease 135 mg (Mebeverine)

Morease 135 mg is a prescription medication formulated with mebeverine, a proven agent for managing the symptoms of irritable bowel syndrome (IBS). Manufactured by Dr Reddy’s Laboratories Ltd, this product is supplied in packs containing 10 tablets per strip, with available pack sizes of 30, 60, or 90 tablets to suit individual treatment plans. The medication is packaged for convenience and stability, ensuring that each tablet retains its potency until the expiration date.

Product Overview

Morease belongs to the class of antispasmodic agents that act directly on the smooth muscle of the gastrointestinal tract. It is indicated specifically for the long‑term management of IBS, a functional disorder characterized by abdominal pain, bloating, and altered bowel habits. The active ingredient, mebeverine hydrochloride, works locally within the gut to relax intestinal muscles without significant systemic absorption, thereby minimizing the risk of widespread side effects. This targeted approach makes Morease a preferred choice for patients seeking relief from chronic IBS symptoms while maintaining a favorable safety profile.

What is Morease 135 mg (Mebeverine)

Morease 135 mg contains the active pharmaceutical ingredient mebeverine, a synthetic derivative of belladonna alkaloids that exerts a direct relaxing effect on visceral smooth muscle. Unlike some other antispasmodics, mebeverine does not cross the blood‑brain barrier to any significant extent, which translates into a lower incidence of central nervous system‑related adverse events. The 135 mg dosage is the standard strength recommended for adult patients with IBS, and each tablet is film‑coated to protect the ingredient from gastric acid, ensuring optimal release in the intestine. The product is marketed under the Dr Reddy’s brand, a globally recognized manufacturer with a commitment to quality manufacturing practices.

Uses and Benefits

The primary use of Morease is to alleviate the discomfort associated with IBS, including abdominal pain, cramping, and irregular bowel movements. Clinical studies have demonstrated that patients receiving mebeverine experience a reduction in the frequency and severity of symptom episodes compared with placebo. In addition to pain relief, Morease helps to normalize stool consistency, reducing episodes of diarrhea or constipation that are common in IBS. The medication’s localized action contributes to a lower systemic exposure, which is associated with fewer drug‑interaction concerns. Patients often report improved quality of life, as they can engage in daily activities without the constant worry of sudden IBS flare‑ups.

How It Works

Mebeverine, the active moiety in Morease, functions by inhibiting the influx of calcium ions into gastrointestinal smooth muscle cells. This inhibition leads to a decrease in intracellular calcium concentration, which in turn reduces the contractility of the intestinal wall. By attenuating excessive muscle spasms, the drug eases the pain and distension that patients experience. The pharmacological effect is largely confined to the gut, as the compound exhibits poor systemic absorption, thereby limiting its impact on other organ systems. This mechanism of action is well documented in pharmacology references such as the FDA’s drug database and peer‑reviewed studies indexed in PubMed, and further details can be found on Drugs.com (https://www.drugs.com/sss/mebeverine.html).

Dosage Guidelines

For adult patients, the usual recommended dose of Morease is 135 mg taken three times daily, preferably before meals. The tablet should be swallowed whole with water, and the dosing schedule may be adjusted by a healthcare professional based on individual response and tolerability. It is important not to exceed the prescribed dose, as higher amounts have not been shown to provide additional benefit and may increase the likelihood of adverse effects. Patients should be instructed to maintain a consistent dosing routine to achieve steady therapeutic levels. If a dose is missed, the patient should take it as soon as remembered unless it is near the time of the next scheduled dose; in that case, the missed dose should be skipped and the regular schedule resumed.

Side Effects

Like all medications, Morease can cause side effects, although most are mild and transient. The most commonly reported adverse events include abdominal discomfort, constipation, nausea, dizziness, and headache. In rare cases, patients may experience allergic reactions such as rash, itching, or swelling, which require immediate medical attention. Additionally, some individuals report dry mouth or blurred vision. It is essential for patients to monitor their response and report any persistent or worsening symptoms to their physician. According to the National Institutes of Health (NIH) database (https://www.ncbi.nlm.nih.gov/books/NBK538281/), serious adverse events are uncommon, but vigilance is advised, particularly in patients with pre‑existing gastrointestinal conditions.

Warnings and Precautions

Before initiating treatment with Morease, patients should inform their healthcare provider of any known allergies to mebeverine or similar medications. The drug should be used with caution in individuals with a history of liver disease, as hepatic impairment may affect drug metabolism. Pregnant or breastfeeding women should consult a physician before use, as safety data in these populations is limited. Morease is not indicated for the treatment of acute diarrhea or infections caused by pathogens, and it should not be used in patients with obstructive gastrointestinal disorders such as bowel stricture. Concomitant use of other antispasmodics or medications that affect gastrointestinal motility should be reviewed by a clinician to avoid potential interactions.

Frequently Asked Questions

1. Can Morease be taken with food? Yes, the medication is typically taken before meals to enhance its local action in the gut, but it can also be taken with a light snack if gastrointestinal tolerance is an issue.
2. How long does it take to notice improvement? Many patients report a reduction in abdominal pain within one to two weeks of consistent use, though individual response times may vary.
3. Is Morease suitable for children? The safety and efficacy of Morease in pediatric populations have not been established; therefore, it is not recommended for use in individuals under 18 years of age without a pediatric specialist’s guidance.
4. Can I use Morease if I have a history of depression? There is no direct contraindication, but patients should discuss all existing medical conditions with their healthcare provider, as certain mental health conditions may influence gastrointestinal symptoms.
5. Where can I find more information about IBS and treatment options? Reliable resources include the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) at the NIH (https://www.niddk.nih.gov/health-information/digestive-diseases/irritable-bowel-syndrome), MedlinePlus (https://medlineplus.gov/irritablebowelsyndrome.html), and the FDA’s drug information page (https://www.fda.gov/drugs).